A Randomized Clinical Trial to Assess the Effect of Statins on Skeletal Muscle Function and Performance: Rationale and Study Design

Overview

Journal Prev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Jul 15

PMID 20626664

Citations 22

Authors

Paul D Thompson

Beth A Parker

Priscilla M Clarkson

Linda S Pescatello

C Michael White

Adam S Grimaldi

Benjamin D Levine

Ronald G Haller

Eric P Hoffman

Affiliations

Soon will be listed here.

Abstract

Hydroxymethylglutaryl-coenzyme A reductase inhibitors or statins are the most effective medications for reducing elevated concentrations of low-density lipoprotein cholesterol (LDL-C). Statins reduce cardiac events in patients with coronary artery disease and previously healthy persons. Current recommendations for LDL-C treatment goals indicate that more patients will be treated with higher doses of these medications. Statins have been extremely well-tolerated in controlled clinical trials but are increasingly recognized to produce skeletal muscle myalgia, cramps, and weakness. The reported frequency of such mild symptoms is not clear, and muscle performance has not been examined with these medications. Accordingly, the present investigation, the Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study, will recruit approximately 440 healthy persons. Participants will be randomly assigned to treatment with atorvastatin 80 mg/d or placebo. Handgrip, elbow and knee isometric and isokinetic strength, knee extensor endurance, and maximal aerobic exercise performance will be determined at baseline. Participants will undergo repeat testing after 6 months of treatment or after meeting the study definition of statin myalgia. This study will determine the effect of statins on skeletal muscle strength, endurance, and aerobic exercise performance and may ultimately help clinicians better evaluate statin-related muscle and exercise complaints.

Citing Articles

Are accelerometer-measured sitting and physical activity times associated with muscle mass and strength in healthy young adults in the UAE?.

Qadah R, Al-Sharman A, Shalash R, Arumugam A Heliyon. 2024; 10(10):e30899.

PMID: 38770340 PMC: 11103532. DOI: 10.1016/j.heliyon.2024.e30899.

Simvastatin-Induced Insulin Resistance May Be Linked to Decreased Lipid Uptake and Lipid Synthesis in Human Skeletal Muscle: the LIFESTAT Study.

Larsen S, Vigelso A, Dandanell S, Prats C, Dela F, Helge J J Diabetes Res. 2018; 2018:9257874.

PMID: 30276217 PMC: 6157137. DOI: 10.1155/2018/9257874.

The influence of resting blood pressure on muscle strength in healthy adults.

Blanchard A, Taylor B, Thompson P, Lepley L, White C, Corso L Blood Press Monit. 2018; 23(4):185-190.

PMID: 29738358 PMC: 6035107. DOI: 10.1097/MBP.0000000000000325.

The effect of high-dose atorvastatin on neural activity and cognitive function.

Taylor B, Dager A, Panza G, Zaleski A, Meda S, Book G Am Heart J. 2018; 197:166-174.

PMID: 29447778 PMC: 6083849. DOI: 10.1016/j.ahj.2017.10.027.

An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.

Lucas J, Bazemore T, Alo C, Monahan P, Voora D PLoS One. 2017; 12(11):e0187809.

PMID: 29155848 PMC: 5695792. DOI: 10.1371/journal.pone.0187809.

References

Thompson P, Clarkson P, Karas R . Statin-associated myopathy. JAMA. 2003; 289(13):1681-90. DOI: 10.1001/jama.289.13.1681. View

Fisher N, Meksawan K, Limprasertkul A, Isackson P, Pendergast D, Vladutiu G . Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation. J Inherit Metab Dis. 2007; 30(3):388-99. DOI: 10.1007/s10545-007-0449-6. View

Pasternak R, Smith Jr S, Bairey-Merz C, Grundy S, Cleeman J, Lenfant C . ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40(3):567-72. DOI: 10.1016/s0735-1097(02)02030-2. View

Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F . SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008; 359(8):789-99. DOI: 10.1056/NEJMoa0801936. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

Guazzi M, Tumminello G, Reina G, Vicenzi M, Guazzi M . Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients. Eur J Clin Invest. 2007; 37(6):454-62. DOI: 10.1111/j.1365-2362.2007.01805.x. View

Tan G, Jensen M, Thornby J, Shanti B . Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004; 5(2):133-7. DOI: 10.1016/j.jpain.2003.12.005. View

Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S . Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993; 33(3):226-9. DOI: 10.1002/j.1552-4604.1993.tb03948.x. View

10.

Young J, Florkowski C, Molyneux S, McEwan R, Frampton C, George P . Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007; 100(9):1400-3. DOI: 10.1016/j.amjcard.2007.06.030. View

11.

Gaist D, Rodriguez L, Huerta C, Hallas J, Sindrup S . Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001; 12(5):565-9. DOI: 10.1097/00001648-200109000-00017. View

12.

Phillips P, Haas R, Bannykh S, Hathaway S, Gray N, Kimura B . Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137(7):581-5. DOI: 10.7326/0003-4819-137-7-200210010-00009. View

13.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View

14.

Agostini J, Tinetti M, Han L, McAvay G, Foody J, Concato J . Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007; 55(3):420-5. DOI: 10.1111/j.1532-5415.2007.01071.x. View

15.

Flint O, Masters B, GREGG R, Durham S . Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997; 145(1):91-8. DOI: 10.1006/taap.1997.8131. View

16.

Wynn R . The top 50 prescription medications dispensed in pharmacies in 2007. Gen Dent. 2008; 56(7):604-7. View

17.

Sirvent P, Mercier J, Lacampagne A . New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008; 8(3):333-8. DOI: 10.1016/j.coph.2007.12.010. View

18.

Liantonio A, Giannuzzi V, Cippone V, Camerino G, Pierno S, Conte Camerino D . Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther. 2007; 321(2):626-34. DOI: 10.1124/jpet.106.118331. View

19.

Pedersen T, Berg K, Cook T, Faergeman O, Haghfelt T, Kjekshus J . Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996; 156(18):2085-92. View

20.

Phillips P, Phillips C, Sullivan M, Naviaux R, Haas R . Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004; 177(1):183-8. DOI: 10.1016/j.atherosclerosis.2004.06.014. View